Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19294596 | 1.00 | FFAR1 (0.55) | FFAR1FFAR4PPARDIDO1PDPK1 | |
| SCHEMBL34466316 | 0.90 | FFAR1 (0.53) | FFAR1FFAR4PPARDIDO1MAPT | |
| SCHEMBL19294598 | 0.87 | KDM4E (0.48) | FFAR1FFAR4LMNAL3MBTL1TSHR | |
| SCHEMBL4666489 | 0.86 | FFAR1 (0.44) | FFAR1FFAR4PPARDIDO1PDPK1 | |
| SCHEMBL28635374 | 0.86 | FFAR1 (0.46) | FFAR1FFAR4LMNAL3MBTL1KEAP1 | |
| SCHEMBL4668893 | 0.84 | FFAR4 (0.49) | FFAR1FFAR4PPARDSRD5A2 | |
| SCHEMBL28666321 | 0.84 | FFAR1 (0.57) | FFAR1FFAR4PPARDIDO1SRD5A2 | |
| SCHEMBL3584403 | 0.83 | KEAP1 (0.63) | FFAR1FFAR4KEAP1ALDH1A1MAPT | |
| SCHEMBL2515837 | 0.82 | TAAR1 (0.54) | FFAR1FFAR4IDO1 | |
| SCHEMBL13886150 | 0.82 | L3MBTL1 (0.56) | FFAR1FFAR4LMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | GENOSCO INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7709511-B2 | Benzothiazolone derivatives | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| EP-1915354-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018461-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | FFAR1 1540/4885FFAR4 1795/4885PPARD 237/4885 |
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | CRBN, PSMB3, PSMB1 | FFAR1 4101/4885FFAR4 4704/4885PPARD 4007/4885 |
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | FFAR1 1540/4885FFAR4 1795/4885PPARD 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.